Bvf Partners L. P/Il Purchases 22,110 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) Director Bvf Partners L. P/Il bought 22,110 shares of the company’s stock in a transaction dated Wednesday, January 11th. The shares were acquired at an average cost of $29.89 per share, for a total transaction of $660,867.90. Following the completion of the transaction, the director now owns 2,491,703 shares of the company’s stock, valued at approximately $74,477,002.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kymera Therapeutics Trading Up 2.9 %

NASDAQ:KYMR opened at $34.54 on Friday. The firm has a market capitalization of $1.90 billion, a PE ratio of -11.75 and a beta of 1.45. The stock has a 50 day moving average of $27.99 and a 200-day moving average of $26.52. Kymera Therapeutics, Inc. has a 52 week low of $13.15 and a 52 week high of $46.22.

Kymera Therapeutics (NASDAQ:KYMR – Get Rating) last posted its earnings results on Thursday, November 3rd. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). The company had revenue of $9.55 million for the quarter, compared to the consensus estimate of $16.42 million. Kymera Therapeutics had a negative net margin of 334.72% and a negative return on equity of 34.20%. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Candriam S.C.A. grew its holdings in Kymera Therapeutics by 13.3% in the 2nd quarter. Candriam S.C.A. now owns 469,860 shares of the company’s stock worth $9,251,000 after buying an additional 55,147 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in Kymera Therapeutics by 108.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 18,665 shares of the company’s stock worth $368,000 after buying an additional 9,730 shares in the last quarter. Woodline Partners LP bought a new position in Kymera Therapeutics in the 2nd quarter worth approximately $1,969,000. Barclays PLC grew its holdings in Kymera Therapeutics by 51.4% in the 3rd quarter. Barclays PLC now owns 352,994 shares of the company’s stock worth $7,685,000 after buying an additional 119,857 shares in the last quarter. Finally, Bank of Montreal Can bought a new position in Kymera Therapeutics in the 2nd quarter worth approximately $1,176,000.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on KYMR. Credit Suisse Group lowered Kymera Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $47.00 to $32.00 in a research report on Monday, December 5th. Wells Fargo & Company lifted their target price on Kymera Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. B. Riley upped their price objective on Kymera Therapeutics from $35.00 to $37.00 in a research note on Thursday, December 15th. Piper Sandler upped their price objective on Kymera Therapeutics from $43.00 to $58.00 in a research note on Wednesday, December 14th. Finally, The Goldman Sachs Group upped their price objective on Kymera Therapeutics from $40.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, December 16th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $41.89.

Kymera Therapeutics Company Profile

(Get Rating)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.